Mucous membrane immunizing agent of polyglycol-inactivated vaccine

A technology of polyethylene glycol and mucosal immunity, which is applied in the direction of antiviral agents, viral antigen components, antibody medical components, etc., can solve problems such as adverse reactions, and achieve the effects of enhancing immunogenicity, improving absorption, and prolonging residence time

Inactive Publication Date: 2005-01-12
FUDAN UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have shown that due to the possibility of antibody enhancement in the pathogenesis of some viruses, IgG antibodies may produce adverse reactions at t

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mucous membrane immunizing agent of polyglycol-inactivated vaccine
  • Mucous membrane immunizing agent of polyglycol-inactivated vaccine

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0015] Example 1 Concentration of polyethylene glycol to inactivate SARS coronavirus

[0016] The pharmaceutical grade polyethylene glycol 6000 is formulated into 35% polyethylene glycol / 1.75M NaCl. Add the inactivated SARS coronavirus (CGMCC No.0977) venom in the amount of 1:5, and incubate at 4°C for 24 hours. Centrifuge at 13,000 rpm for 30 minutes. The supernatant was removed, and the precipitate was dissolved in phosphate buffer (0.01M PBS, PH7.2) to concentrate the virus to 100 times to obtain a crude inactivated SARS coronavirus mucosal immune preparation.

Example Embodiment

[0017] Example 2 Polyethylene glycol concentrates, inactivates and cracks influenza A virus

[0018] Pharmaceutical grade polyethylene glycol 8000 is formulated into 30% polyethylene glycol / 1.75M NaCl. Add the inactivated lysed influenza A virus solution in a ratio of 1:4, and incubate the H3N3 Panama strain (a domestically used production strain in 2003) at 4°C for 24 hours. Centrifuge at 13,000 rpm for 30 minutes. The supernatant is removed, and the precipitate is dissolved in phosphate buffer (0.01M PBS, PH7.2) to concentrate the virus to 50 times to obtain a crude inactivated avian influenza virus mucosal immune preparation.

Example Embodiment

[0019] Example 3 Polyethylene glycol enhances the immunogenicity of nasal drops SARS coronavirus vaccine

[0020] SARS coronavirus (G250) inactivated vaccine, immunization dose: 50μg per mouse; PEG-SARS coronavirus inactivated mucosal immune preparation, immunization dose: 20μg per mouse, immunized Balb / c mice through nasal drops, respectively. The immunization was performed every 2 weeks for a total of 4 immunizations. The mice were sacrificed 2 weeks after the fourth strong immunization, blood was taken to separate the serum, and the trachea and lungs of the mice were lavaged with phosphate buffer. Serum and tracheal-lung lavage fluid were stored at -70°C for testing. Serum is used to detect anti-SARS coronavirus neutralizing antibodies; tracheal-lung lavage fluid is used to detect anti-SARS coronavirus IgA (indirect immunofluorescence method). The results showed that the immunity of the PEG-inactivated vaccine nose drops was significantly higher than that of the inactivated vac...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A mucous immunizing agent is prepared from polyethane glycol (PEG) as adjuvant and deactivated virus liquid. The PEG is used to modify and link thep rotein of deactivated virus, resulting in high stability and immunogenicity, and local mucous immune response.

Description

technical field [0001] The invention belongs to the field of biotechnology and relates to a polyethylene glycol-inactivated vaccine mucosal immune preparation. It specifically relates to the preparation of mucosal immune agent by concentrating inactivated virus vaccine with polyethylene glycol. Background technique [0002] In order to prevent respiratory diseases caused by viral infections, such as severe acute respiratory syndrome (severe acute respiratory syndrome, SARS), viral influenza and viral avian influenza, it is very urgent to develop vaccines. In view of the fact that SARS virus and influenza virus can be cultured in tissue cells and can reach high titers, research on inactivated vaccines is the first choice at home and abroad. Studies have shown that due to the possibility of antibody enhancement in the pathogenesis of some viruses, IgG antibodies may produce adverse reactions at this stage; the injection of whole virus vaccines (such as influenza virus) for so...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/12A61K39/39A61P31/12
Inventor 瞿涤闻玉梅姚忻
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap